For a biotech, there are many ways failure can strike.
One small company suffered what its chief executive called a "stunningly disappointing" failure with a Phase III melanoma treatment and...
Overcoming Disaster: What Biotechs Do When A Lead Asset Fails
Drug candidates fail at an alarming rate. For biotechs that seemingly have their entire future - and tens of millions of investor dollars - tied up in one compound or one clinical trial, failure of a lead asset can mean certain, sudden death. Meet four small companies that had another plan.
More from Archive
More from In Vivo
• By
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
• By
Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.
• By
Trojan Bio’s proprietary platform, based on engineered antibodies that activate the immune system to fight cancer in the same way as common viral infections, won Biomed Israel's 2025 biopharma start-up award. CEO and cofounder Anat Burkovitz said the technology is attracting investors' attention.